Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Accumulated Expenses (2016 - 2025)

Tandem Diabetes Care's Accumulated Expenses history spans 13 years, with the latest figure at $21.0 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 67.23% year-over-year to $21.0 million; the TTM value through Dec 2025 reached $21.0 million, down 67.23%, while the annual FY2025 figure was $21.0 million, 67.23% down from the prior year.
  • Accumulated Expenses reached $21.0 million in Q4 2025 per TNDM's latest filing, up from $12.5 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $64.1 million in Q4 2024 to a low of $6.3 million in Q3 2021.
  • Average Accumulated Expenses over 5 years is $28.2 million, with a median of $26.9 million recorded in 2021.
  • The largest YoY upside for Accumulated Expenses was 977.9% in 2021 against a maximum downside of 79.26% in 2021.
  • A 5-year view of Accumulated Expenses shows it stood at $51.6 million in 2021, then decreased by 24.97% to $38.7 million in 2022, then crashed by 67.1% to $12.7 million in 2023, then skyrocketed by 403.91% to $64.1 million in 2024, then tumbled by 67.23% to $21.0 million in 2025.
  • Per Business Quant, the three most recent readings for TNDM's Accumulated Expenses are $21.0 million (Q4 2025), $12.5 million (Q3 2025), and $51.7 million (Q2 2025).